Lymphoma

Primary Site Histology Behavior Schema Discriminator 1
C000-C424, C470-C509, C511-C608, C619-C631, C637-C689, C691-C694, C698-C699, C739-C749, C760-C809 9590, 9596-9663, 9673-9699, 9702-9719, 9725-9726, 9735, 9737-9738 <Any value>
C440, C442-C449, C510, C609, C632 9590, 9596, 9650-9663, 9673-9679, 9687-9699, 9702-9705, 9714-9717, 9725, 9735, 9737-9738 <Any value>
C700-C729, C751-C753 9590, 9596-9663, 9673-9679, 9687-9698, 9716-9719, 9725-9726, 9735, 9737-9738 3
C750, C754-C759 9590, 9596-9663, 9673-9699, 9702-9719, 9725-9726, 9735, 9737-9738 <Any value> <Any value>
C000-C440, C442-C689, C691-C694, C698-C699, C739-C749, C750, C754-C759, C760-C809 9591 <Any value> 3, 9
C700-C729, C751-C753 9591 3 3, 9
C000-C440, C442-C689, C691-C694, C698-C699, C739-C749, C750, C754-C759, C760-C809 9826-9827 <Any value> <Any value>
C700-C729, C751-C753 9826-9827 3 <Any value>

Notes

9590, 9596-9663, 9673-9699, 9702-9719, 9725-9726, 9735, 9737-9738, 9826-9827 (varying primary sites and histologies) * *See SSDI Manual, Appendix A: Schema ID 00790: Lymphoma for detailed listing of primary site/histology combinations for this schema* 9591 and Schema Discriminator 1: 3, 9 (C000-C440, C442-C689, C691-C694, C698-C809) **Note 1:** The following sources were used in the development of this schema * SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf) * SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/) * Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx * Chapter 79 *Hodgkin and Non-Hodgkin Lymphomas*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois. * Chapter 80 *Pediatric Hodgkin and Non-Hodgkin Lymphomas*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois. **Note 2:** See the following schemas for the listed histologies * C000-C440, C442-C689, C691-C694, C698-C809 (9823): *Lymphoma-CLL/SLL* * C441, C690, C695-C696 (9590-9699, 9673-9699, 9702-9719, 9725-9726, 9734-9738, 9823, 9826-9827, 9930): *Lymphoma Ocular Adnexa* * C440, C442-C449, C510, C609, C632 (9597, 9680, 9708-9709, 9712, 9718-9719, 9726): *Primary Cutaneous Lymphomas* * C700, C710-C719 (9680, 9699, 9702-9715): *Brain* * C701, C709, C720-C725, C728-C729 (9680, 9699, 9702-9715): *CNS Other* * C751-C753 (9680, 9699, 9702-9715): *Intracranial Gland* * 9591 and Schema Discriminator 1: 1, 2 (C000-C440, C442-C689, C691-C694, C698-C809): *HemeRetic* **Note 3:** The Cotswold modification of the Ann Arbor staging system (used in AJCC 6th and 7th editions) has been updated to the *Lugano classification*. The *Lugano classification* includes an E suffix for lymphoma with either localized extralymphatic presentations (Stage IE) or by contiguous spread from nodal disease (Stage IIE). A change from the Cotswold modification of the Ann Arbor Staging System, E lesions do not apply to patients with Stage III nodal disease; or any patient with nodal disease above and below the diaphragm with concurrent contiguous extralymphatic involvement (Stage IV), which was previously Stage IIIE. **Note 4:** Schema includes the preferred terms based on the *2017 WHO Classification of Haematopoietic and Lymphoid Tissues* 9590 Malignant lymphoma, NOS 9591 Non-Hodgkin lymphoma, NOS 9596 B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classic Hodgkin lymphoma 9597 Primary cutaneous follicle centre lymphoma 9650 Classical Hodgkin lymphoma 9651 Lymphocyte-rich classic Hodgkin lymphoma 9652 Mixed cellularity classic Hodgkin lymphoma 9653 Lymphocyte-depleted classic Hodgkin lymphoma 9659 Nodular lymphocyte predominant Hodgkin lymphoma 9663 Nodular sclerosis classic Hodgkin lymphoma 9673 Mantle cell lymphoma 9678 Primary effusion lymphoma 9679 Primary mediastinal (thymic) large B-cell lymphoma 9680 Diffuse large B-cell lymphoma (DLBCL) 9687 Burkitt lymphoma 9688 T-cell/histiocyte-rich large B-cell lymphoma 9689 Splenic marginal zone lymphoma 9690 Follicular lymphoma 9691 Follicular lymphoma, grade 2 9695 Follicular lymphoma, grade 1 9698 Follicular lymphoma, grade 3 9699 Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) 9702 Peripheral T-cell lymphoma, NOS 9705 Angioimmunoblastic T-cell lymphoma 9708 Subcutaneous panniculitis-like T-cell lymphoma 9709 Primary cutaneous peripheral T-cell lymphomas 9712 Intravascular large B-cell lymphoma 9714 Anaplastic large cell lymphoma, ALK-positive 9715 Anaplastic large cell lymphoma, ALK-negative (2021+ only) 9716 Hepatosplenic T-cell lymphoma 9717 Enteropathy-associated T-cell lymphoma 9718 Primary cutaneous anaplastic large cell lymphoma 9719 Extranodal NK/T-cell lymphoma, nasal type 9725 Hydroa vacciniforme-like lymphoma (2018-2020 only, nonreportable as of 2021) 9726 Primary cutaneous gamma-delta T-cell lymphoma (2018-2020 only, see code 9687/3 for 2021+) 9735 Plasmablastic lymphoma 9737 ALK-positive large B-cell lymphoma 9738 HHV8-positive DLBCL, NOS 9766 Lymphomatoid granulomatosis grade 3 (2021+ only) 9826 Burkitt cell leukemia (2018-2020 only, see code 9687/3 for 2021+) 9827 Adult T-cell leukemia/lymphoma

Data Items

Name Default Value Used for Staging NAACCR Item Required By Metadata
Year of Diagnosis <BLANK> No NAACCR #390
dateOfDiagnosis
None
Primary Site <BLANK> Yes NAACCR #400
primarySite
None
Histology <BLANK> Yes NAACCR #522
histologicTypeIcdO3
None
Behavior <BLANK> Yes NAACCR #523
behaviorCodeIcdO3
None
Schema Discriminator 1 <BLANK> Yes NAACCR #3926
schemaDiscriminator1
All SSDI
Tumor Size Clinical 999 No NAACCR #752
tumorSizeClinical
None
Tumor Size Pathological 999 No NAACCR #754
tumorSizePathologic
None
Tumor Size Summary 999 No NAACCR #756
tumorSizeSummary
None
Regional Nodes Positive 99 No NAACCR #820
regionalNodesPositive
None
Regional Nodes Examined 99 No NAACCR #830
regionalNodesExamined
None
LVI 8 No NAACCR #1182
lymphVascularInvasion
None
EOD Primary Tumor 999 Yes NAACCR #772
eodPrimaryTumor
None
EOD Regional Nodes 888 Yes NAACCR #774
eodRegionalNodes
None
EOD Mets 88 Yes NAACCR #776
eodMets
None
SS2018 <BLANK> No NAACCR #764
summaryStage2018
None
Grade Clinical 8 No NAACCR #3843
gradeClinical
CCCR/Canada
COC
NPCR
SEER
SSDI
Grade Pathological 8 No NAACCR #3844
gradePathological
CCCR/Canada
COC
NPCR
SEER
SSDI
Grade Post Therapy Clin (yc) <BLANK> No NAACCR #1068
gradePostTherapyClin
COC
NPCR
SEER
SSDI
Grade Post Therapy Path (yp) <BLANK> No NAACCR #3845
gradePostTherapy
CCCR/Canada
COC
NPCR
SEER
SSDI
B Symptoms 8 No NAACCR #3812
bSymptoms
CCCR/Canada
COC
SEER
SSDI
HIV Status 8 No NAACCR #3859
hivStatus
COC 2018–2020
SEER
SSDI
NCCN International Prognostic Index (IPI) X8 No NAACCR #3896
nccnInternationalPrognosticIndex
COC
SEER
SSDI

Initial Context

Staging Methods

Expand All | Collapse All

Summary Stage 2018

Start

Additional Context
eod_2018_stage_group = 90

Next Step

  1. EOD Primary Tumor
  2. ss2018_t

Next Step

  1. EOD Regional Nodes
  2. ss2018_n

Next Step

  1. EOD Mets
  2. ss2018_m

Next Step

  1. Summary Stage - T only
  2. ss2018_derived

End

Outputs

Name Default Value Description NAACCR Item Metadata
Schema ID 00790 NAACCR #3800
schemaId
None
Derived Version {{ctx_alg_version}} None None
Derived Summary Stage 2018 9 NAACCR #762
derivedSummaryStage2018
None